Welcome to our dedicated page for BETTER THERAPEUTICS news (Ticker: $BTTX), a resource for investors and traders seeking the latest updates and insights on BETTER THERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BETTER THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BETTER THERAPEUTICS's position in the market.
News
Rhea-AI Summary
Better Therapeutics (NASDAQ: BTTX) receives Frost & Sullivan's 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry for its AspyreRx app. The award recognizes the company's unique architecture for scalability and potential expansion to other cardiometabolic conditions. AspyreRx is the first prescription-only digital therapeutic for type 2 diabetes, with FDA authorization for commercial use in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced its commercial launch. The company also reported Q3 financial results and provided updates on key milestones. AspyreRx offers a clinically proven, convenient, and cost-effective treatment option for type 2 diabetes. The company is focused on demonstrating commercial traction and securing payer coverage. Third quarter business highlights include FDA authorization, completion of an evidence program, new patent issuance, commercial launch, study results publication, and data showing superior clinical outcomes. The company also raised additional capital and expects to achieve upcoming milestones related to payer coverage, FDA designation, business development partnership, and financial strengthening.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
-
Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) to release Q3 2023 financial results and host conference call for a business update on November 9, 2023. Register for the call at the provided link. Access codes will be provided upon registration. Webcast link also available for live viewing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) will showcase its prescription digital therapeutic, AspyreRx, at the American College of Lifestyle Medicine's 2023 Annual Conference. AspyreRx is a FDA-authorized treatment for adults with type 2 diabetes, offering a proprietary form of cognitive behavioral therapy. The company will also host an education session to present clinical data and the treatment's mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
-
Rhea-AI Summary
Better Therapeutics launches AspyreRx, the first FDA-authorized digital behavioral therapeutic device for the treatment of type 2 diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
-
Rhea-AI Summary
Better Therapeutics announces positive findings from a recent subgroup analysis of AspyreRx in its pivotal trial for type 2 diabetes. The use of AspyreRx alongside standard of care, including GLP-1 receptor agonists, leads to a substantial reduction in HbA1c compared to control participants. Participants on both GLP-1 medications and AspyreRx also showed greater HbA1c reduction, weight loss, and utilized fewer medications compared to participants on GLP-1 medications without AspyreRx.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
Rhea-AI Summary
Better Therapeutics announces positive results from the LivVita study, showing reduction in liver fat and improved liver health with their prescription digital therapeutics. The company plans to request Breakthrough Device Designation from the FDA by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary
Better Therapeutics completes enrollment of 1,000 participants across two studies to evaluate long-term effectiveness of AspyreRxTM for type 2 diabetes treatment. Initial 6-month data expected by end of 2023. Commercial launch planned for Q4 this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
-
News
Rhea-AI Summary
Better Therapeutics reports Q2 2023 financial results and progress towards key milestones. FDA authorization received for AspyreRxTM to treat type 2 diabetes. Commercial launch expected in Q4. Completed financing transactions totaling $12.5 million in net proceeds. Company sets price for AspyreRx at $750 for a 90-day script.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
Rhea-AI Summary
Better Therapeutics (BTTX) to Release Q2 2023 Financial Results and Host Business Update Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
BETTER THERAPEUTICS INC
Nasdaq:BTTX
BTTX Rankings
BTTX Stock Data
648.74k
21.11M
53.34%
2.95%
3.9%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
United States of America
San Francisco
About BTTX
better therapeutics (f/k/a farewell) is developing prescription digital therapeutics for treating chronic disease. its innovative solution combines software, human coaching augmented by artificial intelligence, and advanced analytics to address the behaviors at the root cause of most chronic conditions, in a manner that can scale rapidly to address millions of covered lives. better’s digital therapeutics are based on well-established evidence, fit within existing clinical treatment guidelines, and can be used with or without other interventions. better believes non-drug treatment options are essential to reducing the unnecessary health and cost burden of chronic disease on individuals, payers, and the nation.